AbbVie Inc. (NEO:ABBV)

Market Cap	448.33B
Revenue (ttm)	82.46B
Net Income (ttm)	5.97B
Shares Out	n/a
EPS (ttm)	3.36
PE Ratio	75.07
Forward PE	14.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,183
Average Volume	4,193
Open	26.66
Previous Close	26.74
Day's Range	26.01 - 26.66
52-Week Range	23.68 - 31.45
Beta	0.49
RSI	48.27
Earnings Date	Jul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD